2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2018
Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study
Jakub J, Peled A, Gray R, Greenup R, Kiluk J, Sacchini V, McLaughlin S, Tchou J, Vierkant R, Degnim A, Willey S. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surgery 2018, 153: 123-129. PMID: 28903167, PMCID: PMC5838709, DOI: 10.1001/jamasurg.2017.3422.Peer-Reviewed Original ResearchConceptsProphylactic nipple-sparing mastectomyNipple-sparing mastectomyRisk-reducing mastectomyPrimary breast cancerBRCA mutationsBreast cancerOncologic safetyContralateral risk-reducing mastectomyNew primary breast cancerOccult primary breast cancerCancer risk-reducing strategiesIpsilateral breast cancerNew breast cancersBreast cancer eventsCohort of patientsNipple-sparing mastectomiesPrimary outcome measureBRCA1/2 mutation carriersFree nipple graftSuperior cosmetic outcomesEvidence-based dataHealth care professionalsMulti-institutional studyNipple-areolar complexProphylactic side
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsCost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analyses
2013
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals Of Surgical Oncology 2013, 20: 3254-3258. PMID: 23975317, DOI: 10.1245/s10434-013-3205-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBRCA mutation prevalenceRace/ethnicityBRCA mutationsGenetic counselingBreast cancerMutation prevalenceGenetic mutationsAfrican AmericansHereditary cancer clinicBRCA mutation statusBRCA genetic mutationPersonalized genetic counselingConclusionsThe prevalenceNCCN guidelinesPrimary outcomeRetrospective reviewTNBC subtypesResultsA totalBRCA2 mutationsCancer clinicMutation statusDemographic dataPrevalenceEthnicity/race